Salah-Eddin Al-Batran
Heidelberg University
293 Papers
2.3K Citations
Salah-Eddin Al-Batran is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 45, co-authored 238 publications.
Chat about Author
Papers
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Salah-Eddin Al-Batran,E. Moorahrend,Christoph Maintz,Thorsten Oliver Goetze,Dirk Hempel,Peter C. Thuss-Patience,Vincent E. Gaillard,Susanna Hegewisch-Becker +7 more
TL;DR: Observation of a second, marginal HER2‐positivity population confirmed the benefit of trastuzumab predominantly for well‐confirmed human epidermal growth receptor 2 (HER2)‐positive tumors and the requirement of reliable HER2 testing.
18
A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours
R.D. Hofheinz,Andreas Hochhaus,Salah-Eddin Al-Batran,A. Nanci,V. Reichardt,Dirk Trommeshauser,M. Hoffmann,M. Steegmaier,Gerd Munzert,Elke Jäger +9 more
TL;DR: BI 2536 is a Plk1 inhibitor with a favorable PK and safety profile at the tested dose and schedule andNeutropenia as a mechanism-related toxicity indicates target inhibition in vivo.
18
Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.
Manish A. Shah,Yelena Y. Janjigian,Claudia Pauligk,Dominique Werner,D. P. Kelsen,Elke Jaeger,Hans-Michael Altmannsberger,E. Robinson,Laura H. Tang,V. V. Barbashina,Salah-Eddin Al-Batran +10 more
TL;DR: Almost 20% of Western patients with advanced gastric cancer are HER2+.
17
741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA
David Cunningham,Salah-Eddin Al-Batran,Irina Davidenko,D. Ilson,Andre M. Murad,Niall C. Tebbutt,Nigel Baker,R. Jain,Tien Hoang +8 more
TL;DR: 17 RILOMET-1: An International Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine as First-Line Therapy in Patients With Advanced MET-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma.
16
AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer.
Melanie Kripp,Nicole Prasnikar,Ursula Vehling-Kaiser,Julia Quidde,Salah-Eddin Al-Batran,Alexander Stein,Kai Neben,Carla Hannig,Hans Werner Tessen,Tanja Trarbach,Axel Hinke,Ralf-Dieter Hofheinz +11 more
TL;DR: Ierythromycin cannot be regarded as an alternative to doxycycline as prevention of EGFR-related skin toxicity and overall quality of life was comparable between both arms.
16